Maltron International

Maltron International Ltd is a UK-based medical technology company and a global pioneer in non-invasive fluid, body composition, and metabolic monitoring. With over four decades of scientific expertise, Maltron has established itself as a leader in advanced Multi technology diagnostic systems designed for real-world clinical decision-making at the point of care.

Maltron is best known for its flagship platforms, the BioScan touch i8 and BioScan touch i8 nano, which represent the world’s most advanced multi-technology point-of-care monitors capable of assessing fluid distribution, body composition, and electrolytes in a single, rapid, non-invasive measurement. Unlike other conventional devices, Maltron systems are engineered for clinical environments, supporting adult, paediatric, neonatal, and preterm populations without exclusion.

The company’s proprietary technology integrates multi technology this enables clinicians to move beyond simple weight or oedema assessment toward true precision fluid and metabolic management.

Maltron works closely with hospitals, universities, and key opinion leaders worldwide, supporting clinical research, multi-centre studies, and guideline-driven innovation across nephrology, cardiology, intensive care, neonatology, oncology, nutrition, and metabolic medicine. Its solutions are used in acute care, chronic disease management, and research settings, helping clinicians detect risk earlier, guide interventions, and monitor response in real time.

Operating under a robust ISO 13485 quality management system and aligned with international regulatory frameworks including UKCA, CE (EU MDR), and global market requirements, Maltron is committed to safety, scientific integrity, and continuous innovation.

Maltron International Ltd is driven by a single mission: to deliver clinically meaningful, non-invasive diagnostics that improve patient outcomes by bringing advanced physiology insight directly to the bedside.